Post

IT and bioinformatics companies for the clinical trials industry

Digitalising clinical trials can improve accessibility and engagement for participants, as well as data collection and analytics. It has the …

Sanofi advances NK cell engager to Phase II for blood cancer treatment

Sanofi has moved its natural killer (NK) cell engager candidate SAR443579/IPH6101 to a Phase II trial evaluating the drug’s use …

EMulate’s radiofrequency device proves effective in GBM mouse models 

Seattle-based device company EMulate Therapeutics has announced that a study proving the effectiveness of its radiofrequency energy device in mouse …

MaaT Pharma’s GvHD drug boasts 18-month overall survival improvement

Lyon, France-based MaaT Pharma has announced positive 18-month data for its lead candidate MaaT013 showing an overall survival advantage in …

Sight Sciences touts eye pressure reduction with glaucoma OMNI device

US-based Sight Sciences has published the two-year post-surgical outcomes of its minimally invasive glaucoma surgery device, the OMNI surgical system. The …